Literature DB >> 3669763

The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.

S D Griffiths1, J C Cawley.   

Abstract

The natural killer (NK) activity of peripheral blood mononuclear cells against K562 targets was variable in 10 untreated patients with hairy cell leukemia and was inversely related to the number of hairy cells (HCs) present. After therapy with alpha-interferon (IFN-alpha) NK activity in vitro was equivalent to that of normal controls. It is suggested that the low activity often seen before treatment is attributable to dilution of NK cells by large numbers of inactive HCs and that this diluting effect is reduced as HCs disappear from the blood during IFN-alpha treatment. HCs was consistently resistant to NK lysis by normal or hairy cell leukemia allogeneic and autologous mononuclear cells, despite whether effector or target cells had been pretreated with IFN-alpha. Cold-target inhibition and direct binding experiments showed that HCs do not bind to NK effectors. It is therefore concluded that NK cells play no direct role in the progressive disappearance of HCs seen in patients receiving IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3669763

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  3 in total

1.  Hairy cells are not lysed by autologous LAK cells.

Authors:  J Demeter; M Benczur
Journal:  Blut       Date:  1989-01

2.  Biochemical and immunological responses of hairy cell leukemia patients to interferon beta.

Authors:  A M Liberati; M Horisberger; M Schippa; F Di Clemente; M Fizzotti; S Filippo; M G Proietti; S Arzano; P Berruto; L Palmisano
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders.

Authors:  H E Heslop; A C Bianchi; F T Cordingley; M Turner; W Chandima; C P De Mel; A V Hoffbrand; M K Brenner
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.